Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8086 to 8100 of 8950 results

  1. Emphysema - inhaled alpha-1 antitrypsin [ID1200]

    Discontinued Reference number: GID-TA11179

  2. Subcutaneous atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after platinum-based chemotherapy TS ID 11801

    Discontinued Reference number: GID-TA11180

  3. Exploratory work regarding the use of bevacizumab in the treatment of eye conditions [ID422]

    Discontinued Reference number: GID-TA11205

  4. Erlotinib in combination with bevacizumab for the second line treatment of advanced or metastatic non-small cell lung cancer [ID43]

    Discontinued Reference number: GID-TA11207

  5. Ovarian (epithelial), fallopian, peritoneal cancer - paclitaxel (encapsulated in XR-17 [ID565]

    Discontinued Reference number: GID-TA11209

  6. Canakinumab and tocilizumab for treating systemic juvenile idiopathic arthritis [ID983]

    Discontinued Reference number: GID-TA11241

  7. Sacubitril valsartan for treating chronic heart failure with preserved ejection fraction [ID1606]

    Discontinued Reference number: GID-TA11257

  8. Rolofylline for the treatment of acute heart failure [ID96]

    Discontinued Reference number: GID-TA11258

  9. Bavituximab for treating non-squamous non-small-cell lung cancer after platinum-based chemotherapy [ID975]

    Discontinued Reference number: GID-TA11260

  10. Ataluren for treating cystic fibrosis in people with a CFTR gene nonsense mutation [ID955]

    Discontinued Reference number: GID-TA11262

  11. Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]

    In development Reference number: GID-TA11272 Expected publication date: TBC

  12. Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]

    In development Reference number: GID-TA11274 Expected publication date: TBC

  13. GID-MT563 NPi-200 for pupillary light reflex in critical care patients

    Discontinued Reference number: GID-MT563

  14. Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]

    In development Reference number: GID-TA11443 Expected publication date: TBC

  15. Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]

    In development Reference number: GID-TA11301 Expected publication date: TBC